Common Shares, No Par Value
- Symbol
- BHC
- Exchange
- NYSE
- Classification
- COMMON
Current Report · Items 5.02, 7.01, 9.01 · 8-K
Bausch Health Companies Inc
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On June 26, 2026, Mr. Michael Goettler notified Bausch Health Companies Inc.…
Press release in this filing
Michael Goettler Resigns from Bausch Health’s Board of Directors →Company context
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.
Current securities
Registered securities in this filing
Bausch Health Companies Inc. · 8-K · Filed 2026-07-01
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On June 26, 2026, Mr. Michael Goettler notified Bausch Health Companies Inc. (the “Company”) of his decision to resign from the Board of Directors (the “Board”), effective June 30, 2026, in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC.
Mr. Goettler’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01
Regulation FD Disclosure
A copy of the press release, dated July 1, 2026, announcing Mr. Goettler’s resignation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in the preceding paragraph, as well as Exhibit 99.1 hereto, is being “furnished” pursuant to Item 7.01 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and is not incorporated by reference into any Company filing, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing and regardless of any general incorporation language in such filing.